119th Congress · introduced in the House · Apr 6, 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Official title from Congress.gov
Latest action (Oct 14, 2026): Message on Senate action sent to the House.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Reported to House (Jul 9, 2026)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
• grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
• grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
• a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Show the full summary (2 more paragraphs)Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Message on Senate action sent to the House.
Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Considered as unfinished business. (consideration: CR H5159)
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 637.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Department of Health and Human Services · Drug therapy · Food and Drug Administration (FDA) · Government information and archives · Health programs administration and funding · Internet, web applications, social media · Medical research · National Institutes of Health (NIH) · Neurological disorders · Public-private cooperation · Research administration and funding
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsOrdered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Coverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
12 citations.
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Veterans
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
I AM ALS · lobbying firm or registrant: I AM ALS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$40,000
Spent on own lobbying
(H.R.8205 / S.4472) Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036)…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX) · lobbying firm or registrant: TWENTY-FIRST CENTURY GROUP, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Veterans
$24,000
Paid to lobbying firm
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
I AM ALS · lobbying firm or registrant: I AM ALS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 13, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
(H.R.8205 / S.4472) Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036)…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
I AM ALS · lobbying firm or registrant: I AM ALS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
(H.R.8205) Reauthorization and fully funding of the ACT for ALS (Public Law 117-79) for continued access to promising treatments and research. (S.925/H.R.2036) Credit fo…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE ALS ASSOCIATION · lobbying firm or registrant: THE ALS ASSOCIATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 13, 2026 · issue area: Health Issues
$30,000
Spent on own lobbying
H.R. 8205 - To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing